Clinical Trial Update: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL [Phase 3]

View source ↗

Summary

Phase 3 study comparing bendamustine-rituximab (BR) alone versus BR plus acalabrutinib in previously untreated mantle cell lymphoma; the trial is currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Lymphoma, Mantle Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING